Media

Wilson Therapeutics presents encouraging clinical data on Decuprate® at the Congress of the European Academy of Neurology

GenSight Biologics announces the registration of its document de base in relation to its planned IPO on Euronext’s regulated market in Paris

NORDIC NANOVECTOR TO HOST CAPITAL MARKETS DAY IN OSLO ON 31 MAY 2016

NORDIC NANOVECTOR ASA: NEW BOARD MEMBERS ELECTED BRINGING FURTHER EXPERTISE IN THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE CANCER THERAPIES

NORDIC NANOVECTOR ASA FIRST QUARTER 2016 RESULTS: STRONG PROGRESS ON ALL PRIORITIES AND EXECUTION ON TRACK

Wilson Therapeutics AB (PUBL) Interim Report January 1 – March 31, 2016

STELVIO Trial Shows Sustained Benefits for Emphysema Patients One Year After Treatment with Zephyr® Endobronchial Valves

Nordic Nanovector announces first patient enrolled in the last cohort (Arm 4) of expanded Phase 1/2 study of Betalutin® in NHL patients

Wilson Therapeutics announces that the ongoing Phase II study has been fully enrolled

Strongbridge Biopharma plc Reports First Quarter 2016 Financial Results